PBPIA
EVMN

Pivotal bioVenture Partners Investment Advisor’s Evommune Inc EVMN Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6M Hold
1,926,943
– – 8.32% 5
2026
Q1 		$44.3M Hold
1,926,943
– – 15.83% 3
2025
Q4 		$33M Buy
+1,926,943
New +$36.2M 12.75% 4

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's EVMN Position: Q2 2026 in Review

Pivotal bioVenture Partners Investment Advisor held its Evommune Inc (EVMN) position steady in Q2 2026 at 1,926,943 shares worth $25.6M. The position accounts for 8.32% of the portfolio, ranked #5.

Pivotal bioVenture Partners Investment Advisor first reported a position in EVMN in Q4 2025 and has held it in 3 quarters since. The position peaked at $44.3M in Q1 2026. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Pivotal bioVenture Partners Investment Advisor held 1,926,943 shares of Evommune Inc worth $25.6M as of Q2 2026.
  • Pivotal bioVenture Partners Investment Advisor left its Evommune Inc share count unchanged in Q2 2026.
  • Evommune Inc made up 8.32% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q2 2026, its #5 holding.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Evommune Inc in Q4 2025 and has held it in 3 quarters since.
  • Pivotal bioVenture Partners Investment Advisor's Evommune Inc position peaked at $44.3M in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2026, filed 13 Aug 2026.